Geraghty is Chairman of two other biotech companies: rEvo Biologics (the successor company to GTCB) and IDRA. This appointment makes me somewhat less favorably inclined toward JNP.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”